Form 4: Cytek CTO Yan Ming Boosts Stake with RSU Vesting

Cytek Biosciences' Chief Technology Officer, Yan Ming, increased direct beneficial ownership of common stock by 15,908 shares following the vesting and conversion of Restricted Stock Units on November 18, 2025.

Summary

• Yan Ming, Cytek Biosciences' Chief Technology Officer and Director, reported transactions on November 18, 2025.
• Ming acquired a total of 21,031 shares of common stock through the vesting and conversion of Restricted Stock Units (RSUs).
• Concurrently, 5,123 shares were disposed of at a price of $5.53 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Ming's direct beneficial ownership of Cytek Biosciences common stock increased to 6,073,327 shares.
• Remaining unvested RSUs for various awards are 1,332, 39,277, 51,569, and 82,175, respectively.

Sentiment

Score: 7

Explanation: The filing indicates a routine executive compensation event where a key officer's equity stake increased, which is generally positive for aligning interests. The tax-related sales are standard and not indicative of negative sentiment.

Positives

• Increased beneficial ownership by a key executive (CTO and Director) signals confidence in the company's future.
• The vesting of RSUs is a standard component of executive compensation, aligning management's interests with shareholders.

Negatives

• A portion of the vested shares (5,123 shares) was sold to cover tax liabilities, which is a common practice but reduces the net increase in direct ownership.

Future Outlook

NA

Industry Context

This filing reflects routine executive compensation practices within the biotechnology and life sciences industry, where Restricted Stock Units are commonly used to incentivize and retain key personnel. The vesting and subsequent tax-related sales are standard events for executives receiving equity awards.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a significant component of executive compensation is a common practice across the technology and life sciences sectors, aligning executive incentives with long-term shareholder value, similar to practices at companies like Thermo Fisher Scientific or Danaher Corporation.
• The disposition of shares to cover tax withholding obligations upon RSU vesting is a standard and expected event for executives, consistent with practices observed at most publicly traded companies in the U.S.

Stakeholder Impact

• Shareholders: Increased alignment of a key executive's interests with shareholders due to higher direct equity ownership.
• Employees: Reinforces the company's executive compensation structure, potentially signaling stability in leadership.

Next Steps

• Continued vesting of remaining Restricted Stock Units on scheduled quarterly and annual dates as outlined in the RSU award explanations.

Key Dates

Recommendation

This Form 4 filing details a routine vesting of Restricted Stock Units and subsequent tax-related sales by a key executive. While the net increase in beneficial ownership is a positive signal of alignment, these transactions are expected and do not provide new fundamental information to warrant a change in investment recommendation. The filing does not present any new catalysts or risks that would significantly alter the company's investment profile, thus a 'hold' recommendation remains appropriate based solely on this filing.

Keywords

Cytek Biosciences, CTKB, Yan Ming, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Executive Compensation, Beneficial Ownership, Chief Technology Officer